PPG: To treat or not to treat

Article

Risk assessment best guide for determining management of pre-perimetric glaucoma

Although the two glaucoma specialists presented opposing views - Dr Greenfield taking the affirmative position and Dr Singh presenting arguments against the need to diagnose and treat PPG - their discussions reflected the need for the decision to be individualized based on risk assessment and the importance of continued follow-up.

In deciding the approach to management of PPG, Dr Greenfield advocated applying the 'Principle of the 3 Rs' that considers: 1) eyes with PPG are probably at greater Risk for developing progressive visual field changes, 2) the need to measure the Rate of change, and 3) the need to Re-evaluate these eyes constantly for risk factors associated with progression.

"However, there is also a role for observation in eyes with minimal risk of loss in vision-related quality of life, a slow velocity of change, or patients with reduced life expectancy," Dr Greenfield added.

Evidence in favour of treatment

One of the limitations in guiding therapeutic decisions for PPG is that there are no randomized controlled trials that specifically enrolled patients with PPG. However, it can be assumed that a subset of patients in the Ocular Hypertension Treatment Study (OHTS) had undetected PPG, and in the Diagnostic Innovations in Glaucoma Study (DIGS), there was a subset of patients with baseline retinal nerve fibre layer (RNFL) atrophy. Data available from these cohorts indicate they have a greater risk of disease progression than their counterparts without evidence of structural abnormality, according to Dr Greenfield.

In DIGS, patients with suspected glaucoma with baseline RNFL atrophy had a four-fold increased risk of developing perimetric disease during follow-up, and those whose optic nerves showed glaucomatous progression over time had a 26-fold increased risk of developing visual field loss.

"Imaging plays a critical role for assessing the risk of visual field loss in eyes with PPG," Dr Greenfield said. "Development of a visual field defect can often be predicted by identifying eyes with an abnormally thin retinal nerve fiber layer thickness using either scanning laser polarimetry or time-domain OCT, according to findings from the DIGS study."

"Data from the Confocal Scanning Laser Ophthalmoscopy (CSLO) ancillary study of OHTS showed the risk for developing abnormal visual fields was increased nine-fold in eyes with abnormal baseline optic disc topography. Furthermore, in OHTS, two of the five originally described risk factors for converting to glaucoma, increased cup–disc ratio and visual field pattern standard deviation, are surrogates of PPG," he added.

Monitoring of patients with PPG

"Careful surveillance of patients for progression is important to identify those who are undergoing fast progression. Structural and functional data from at least five exams are needed to calculate the rate of progression. Frequent re-examination is important to assess the development of new risk factors, such as increased IOP or optic disc hemorrhage, that might alter the threshold for initiating therapy," Dr Greenfield said.

"Fundamentally, we need to individualize therapy based on life expectancy and risk assessment," he continued. "Data from a recently published analysis from the OHTS showed delayed treatment in eyes at the highest risk for developing change increased the cumulative incidence of developing visual field loss, the incidence of bilateral visual field loss, and hastened the onset of developing glaucoma by as much as 2.5 years."

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.